Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden-Reference-Cited by-同舟云学术

Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden

Published:2024-03-26 Issue:1 Volume:27 Page:483-491
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Ralph Lewis¹,Young Kate²^ORCID,Upadhyay Navneet²,Prabhu Vimalanand Shrikant²^ORCID,Ljungcrantz Christina³^ORCID,Massaad Rachid⁴,Xu Ruifeng²,Giertz Anna⁵^ORCID,Merchant Adil¹,Orlowski Robert²,Duska Linda⁶

Affiliation:

1. Health Economic Analysis, Lumanity, Sheffield, UK

2. Merck Research Laboratories, Merck & Co., Inc, Rahway, NJ, USA

3. Market Access, MSD Sweden, Stockholm, Sweden

4. Merck Research Laboratories, Merck Sharp & Dohme (Europe), Brussels, Belgium

5. Real World Evidence and Analytics, Quantify Research, Health Economics, Stockholm, Sweden

6. Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA, USA

Funder

Merck Sharp & Dohme LLC

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2024.2329022

Reference29 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Regionala Cancercentrum. Endometrie-/corpuscancer – Nationellt vårdprogram. 2022. https://cancercentrum.se/globalassets/cancerdiagnoser/gynekologi/livmoderkroppscancer/vardprogram/nationellt-vardprogram-endometriecancer.pdf.

3. Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis

4. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

5. European Medicines Agency. Keytruda (pembrolizumab). 2022. https://www.ema.europa.eu/en/documents/overview/keytruda-epar-medicine-overview_en.pdf.